We’re excited to announce the BD and Decode Health strategic partnership that will accelerate innovation and advance precision medicine. Together, we’re working to advance at home collections for molecular biomarkers like RNA using a simple finger stick. Our work could unlock groundbreaking innovations for biomarker discovery and routine screening across multiple disciplines from oncology to autoimmune diseases and beyond. At-home testing can significantly improve efficiency and enhance diversity in clinical trials, speeding the development of potentially life-saving treatments.

Decode Health was recently honored for its commitment to advancing precision medicine and extraordinary promise for future endeavors with a 2022 Nashville Entrepreneur Center NEXT Award for healthcare innovation.

Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.

New members bring cross-industry insights to the company Nashville, Tenn. – Nov. 11, 2020 – Chase Spurlock, PhD, founder and CEO of Decode Health, announced the addition of two members to the company's Strategic Advisory Board. [read more...]

One-year-old technology startup Decode Health has developed a predictive artificial intelligence platform that identifies emerging trends in the COVID-19 outbreak, providing governments and other organizations early insights to where resources need to be allocated to provide targeted outreach among high-risk populations.